Gastric Emptying Breath Test for GAVE
(GAVE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to learn more about Gastric Antral Vascular Ectasia (GAVE), a condition involving enlarged blood vessels in the stomach that can cause bleeding, abdominal pain, and nausea. Researchers seek to understand the frequency of these symptoms and their relationship to stomach function. Participants will undergo a gastric emptying breath test to measure how quickly their stomach empties solids. The trial seeks individuals diagnosed with GAVE and either cirrhosis or chronic kidney disease, excluding those with other underlying diseases like diabetes.
As an unphased study, this trial offers participants the chance to contribute to foundational research that could enhance understanding and treatment of GAVE.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What prior data suggests that the Gastric Emptying Breath Test is safe?
Research has shown that the gastric emptying breath test is generally safe and easy to administer. This test measures how quickly the stomach empties food by analyzing carbon dioxide in the breath. As a non-invasive procedure, it avoids surgery or entering the body, typically resulting in fewer side effects.
Studies have not reported any major problems from this test. Its use in hospitals for other conditions confirms its safety. This test is often preferred because it does not involve radiation, unlike some other tests.
Overall, the gastric emptying breath test is considered safe and provides a reliable way to assess stomach function in various conditions.
Why are researchers excited about this trial?
Researchers are excited about this trial because it uses a gastric emptying breath test to assess stomach function in patients with and without Gastric Antral Vascular Ectasia (GAVE) who also have cirrhosis or chronic kidney disease. This non-invasive test is unique as it measures how quickly the stomach empties solids by detecting labeled carbon dioxide in a patient’s breath. Unlike more invasive diagnostic procedures, this method is simpler and more comfortable for patients, potentially offering a new way to understand and manage upper GI symptoms related to GAVE.
What evidence suggests that the Gastric Emptying Breath Test is effective for GAVE?
Research has shown that the Gastric Emptying Breath Test effectively measures how quickly the stomach empties food. This is crucial for conditions like Gastric Antral Vascular Ectasia (GAVE) because it can help identify problems with stomach function. In this trial, participants with and without GAVE, who also have cirrhosis or chronic kidney disease, will undergo the test. The test measures the amount of a special type of carbon dioxide in the breath, indicating how fast food moves through the stomach. While direct proof that this test can treat GAVE is not yet available, it aids doctors in understanding the stomach's role in the condition. Knowing the stomach's emptying rate can be important for managing symptoms like stomach pain and nausea associated with GAVE.
Who Is on the Research Team?
Xiao Jing Wang, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Assessment
Participants undergo a gastric emptying breath test to measure how quickly the stomach empties solids
Follow-up
Participants are monitored for safety and effectiveness after assessment
What Are the Treatments Tested in This Trial?
Interventions
- Gastric Emptying Breath Test
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Patients without Gastric Antral Vascular Ectasia with cirrhosis or chronic kidney disease will undergo a gastric emptying breath test. This test is designed to show how quickly the stomach empties solids by measuring labeled carbon dioxide in a patient's breath.
Patients with Gastric Antral Vascular Ectasia with cirrhosis or chronic kidney disease will undergo a gastric emptying breath test. This test is designed to show how quickly the stomach empties solids by measuring labeled carbon dioxide in a patient's breath.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Cairn Diagnostics
Industry Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.